POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Acrivon Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of precision oncology medicines. The company’s primary focus is on advancing its lead candidate ...

Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative Phosphoproteomics machine learning for integrated comprehensive analyses across all ...

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor ...

To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 ...

Ring-shaped extrachromosomal DNA is implicated in many cancers. Rachel Brazil talks to the scientists trying to uncover their ...

Acrivon Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of precision oncology medicines. The company’s primary focus is on advancing its lead candidate, ...